Individualizing Therapeutic Options and Achieving Goals in Chronic Lymphocytic Leukemia (CLL)
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: March 17, 2015
Expiration Date: March 17, 2016
Expected time to complete this activity as designed: 120 minutes
There are no fees for participating in or receiving credit for this online activity.
Drs. Jan Burger, Jennifer Brown, Peter Hillmen, and Thomas Kipps discuss critical information, expert guidelines, and recommendations concerning evolving treatment paradigms in chronic lymphocytic leukemia (CLL) as well as address current clinical controversies. This accredited activity presents the most up-to-date data, recommendations, and practice standards in order to help participants gain additional knowledge and understanding required to assess all possible therapeutic strategies for patients with CLL.
This activity is designed for community oncologists who may provide care to patients with CLL.
Upon completion of this educational activity, participants should be able to:
- Incorporate data for current and emerging prognostic clinical and molecular markers into treatment planning and monitoring processes for patients with CLL (knowledge, competence, performance, patient outcomes);
- Select and implement personalized treatment strategies, considering medical fitness status and other presenting patient characteristics (knowledge, competence, performance);
- Compare and contrast emerging single and combination therapies for the treatment of CLL including safety and efficacy data to improve patient care (knowledge, competence, performance, patient outcomes);
- Utilize the outcomes of recent clinical trials to individualize therapeutic strategies for patients with CLL, focusing on treatment sequencing and identifying the most appropriate therapies for each patient (knowledge, competence, performance, patient outcomes).
Introduction and Case Presentation – Jan A. Burger, MD, PhD
Prognostic and Predictive Factors in CLL – Thomas J. Kipps, MD, PhD
The Value of Traditional Chemotherapy – Peter Hillmen, MD, FRCP, FRCPath, PhD
Changing Future Treatment Paradigms: The Role of Novel Therapies – Jennifer R. Brown, MD, PhD
Case Review – Jan A. Burger, MD, PhD
Instructions for Participation and Credit
This activity is eligible for credit through March 17, 2016. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation.
Jan A. Burger, MD, PhD
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Dr. Jan Burger received his medical degree and his PhD from Albert Ludwigs University, School of Medicine, Freiburg, Germany. He completed his residency in internal medicine at Freiburg University Hospital, and a postdoctoral fellowship in hematology/oncology at the University of California, San Diego. Dr. Burger is an associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Board certified in hematology/oncology and internal medicine, Dr. Burger holds memberships in the American Society of Hematology (ASH), German Society of Hematology/Oncology, American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), European Hematology Association (EHA), and the Southwest Oncology Group (SWOG). He is on the editorial review board of American Journal of Blood Research, and is an ad hoc journal reviewer for more than 20 publications including the British Journal of Hematology, Cancer Research, Journal of Clinical Oncology, Cancer, The Lancet, and The New England Journal of Medicine. In addition, he has written more than 100 peer-reviewed original research articles and abstracts.
Dr. Burger’s interests are the treatment of patients with acute and chronic leukemias and myelodysplastic syndromes, as well as his research program that develops pre-clinical and clinical concepts to target the microenvironment in acute and chronic leukemias. His current experimental focus is the function of B-cell chemokine receptors, interactions with the B-cell receptor, and downstream signaling pathways.
Jennifer R. Brown, MD, PhD
Chronic Lymphocytic Leukemia Center
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Dr. Jennifer Brown completed her medical degree and PhD in molecular genetics at Harvard Medical School, Boston. She served as an intern and resident in internal medicine at Massachusetts General Hospital and then completed her fellowship in hematology and medical oncology at Dana-Farber Cancer Institute. She is an assistant professor of medicine at Harvard Medical School, and an attending physician in the Division of Hematologic Malignancies at Dana-Farber. Dr. Brown has an active clinical research program focused on chronic lymphocytic leukemia (CLL), with particular interest in novel therapies and inherited predisposition to CLL and lymphoma.
Peter Hillmen, MD, FRCP, FRCPath, PhD
Professor, Experimental Hematology
St. James’s University Hospital
Leeds Teaching Hospitals
Dr. Peter Hillmen received his medical degree from Leeds Medical School and his PhD from the University of London for research into paroxysmal nocturnal hemoglobinuria (PNH). He also trained in hematology at Hammersmith Hospital, London, followed by research at the Royal Postgraduate Medical School, London. Dr. Hillmen is the professor of experimental hematology at the University of Leeds and an honorary consultant hematologist at the Leeds Teaching Hospitals NHS Trust based at St James’s University Hospital, Leeds.
A fellow of the Royal College of Pathologists and the Royal College of Physicians, Dr. Hillmen is also a member of the British Society for Haematology, European Hematology Association, and the American Society of Hematology. He is the chairman of the NCRI CLL sub-group responsible for CLL trials in the UK, and is a member of the NCRI Haematological Oncology Clinical Studies Group. In addition, he is chairman of the International PNH Interest Group and of the executive committee of the Global PNH Registry.
Dr. Hillmen has published over 130 papers in international, peer-reviewed journals, and has authored or co-authored several reviews and book chapters on the subjects of PNH and chronic lymphocytic leukemia (CLL). His clinical and research interests include PNH and CLL and he is the principal investigator in several national and international phase II and III trials for both CLL and PNH.
Thomas J. Kipps, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Deputy Director of Research
UC San Diego Moores Cancer Center
La Jolla, California
Dr. Thomas Kipps received his medical degree and PhD in immunology at Harvard Medical School, and had his residency and fellowship training in internal medicine, hematology, and genetics at Stanford University. Dr. Kipps is a professor in the Department of Medicine, deputy director of research, as well as interim director at UC San Diego Moores Cancer Center.
Dr. Kipps is a diplomate of the National Board of Examiners, and the National Board of Internal Medicine, and the National Subspecialty Board of Internal Medicine in Hematology. He is an adjunct member in the Department of Molecular and Experimental Medicine at Scripps Clinic and Research Foundation, and a member of the Lymphoma Research Foundation Mantle Cell Lymphoma Consortium (MCLC). In addition Dr. Kipps holds memberships in the American Federation for Clinical Research, American Society of Hematology, Federation of American Societies for Experimental Biology, Association of American Physicians, and the American Association for Cancer Research, among others. He is on the editorial board of Blood, and Cancer Gene Therapy, and is a reviewer for The New England Journal of Medicine. He is the author of more than 300 publications. A major focus of Dr. Kipps’ research is the immunobiology and genetics of human B-cell malignancies, with emphasis on chronic lymphocytic leukemia (CLL).
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Accreditation Council for Continuing Medical Education has announced standards and guidelines to insure that individuals participating in CME activities are aware of program chair(s), planning committee members, faculty/teacher/author, or CME activity reviewer relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.
The University of Texas MD Anderson Cancer Center has, through a formal review process, resolved all conflicts of interest prior to this activity.
Dr. Jan Burger has received honoraria related to formal advisory activities and as a consultant from Celgene Corporation, Gilead, NOXXON Pharma AG, and Pharmacyclics, Inc. He has received grant support related to research activities from Celgene and Pharmacyclics.
Dr. Jennifer Brown has received honoraria as a consultant from Boehringer Ingelheim GmbH, Celgene Corporation, Emergent BioSolutions Inc., GlaxoSmithKline plc, Genentech (A Member of the Roche Group), Gilead, Janssen Pharmaceuticals, Inc., MorphoSys, and Novartis AG.
Dr. Peter Hillmen has received honoraria related to speakers’ bureau activities from Janssen Pharmaceuticals, Inc. He has received grant support related to research activities from Janssen and Pharmacyclics, Inc.
Dr. Thomas Kipps has disclosed no relevant financial relationships.
Planning Committee Disclosures
Program planning committee members, Joan Meyer, RN, MA, CCMEP, Arielle Fera, Christine Mettille, Sheri Sturgis, and Shirley Roy, MPH, have indicated no financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or with anyone who may financially support this CME activity. Program planning committee member, Jan Burger, MD, PhD has received honoraria related to formal advisory activities and as a consultant from Celgene Corporation, Gilead, NOXXON Pharma AG, and Pharmacyclics, Inc. He has received grant support related to research activities from Celgene and Pharmacyclics.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Burger and Dr. Hillmen have indicated that they do not intend to discuss investigational or off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Brown and Dr. Kipps have indicated that they do intend to discuss investigational or off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc. and The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center acknowledges support from the Leukemia & Lymphoma Society-->
This activity has been supported by educational grants from Pharmacyclics, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and from Teva Pharmaceuticals.
©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.